APOE4 is a version of the APOE gene that raises risk for late-onset Alzheimer's. A risk percentage means higher odds of memory loss, not a guarantee it will happen. Relative risk sounds large, while lifetime chance stays more concrete. The common estimates run about 9% with no copy, 20–30% with one copy, and 55–60% with two copies by about age 85, according to the Mayo Clinic overview in Mayo Clinic's Alzheimer's genes guide.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- What does having one or two copies mean?
- Why is relative risk different from lifetime chance?
- Does APOE4 change when symptoms appear?
- What can a carrier practically do next?
What does having one or two copies mean?
Everyone inherits two APOE copies, one from each parent. The gene has three common forms — e2, e3 and e4 — with e3 found in more than half the general population. About 25% of people carry one APOE4 copy and about 2–3% carry two copies, according to the National Institute on Aging in the NIA report on APOE4 and dementia risk. One copy raises Alzheimer's dementia risk roughly 2- to 4-fold.
Two copies raise it roughly 8- to 12-fold, according to the National Institute on Aging summary in the NIA summary of APOE4 risk findings. Think of copies as dose. One copy means increased susceptibility. Two copies means much stronger susceptibility, especially after age 65.
Why is relative risk different from lifetime chance?
Relative risk compares groups. It says how many times more likely Alzheimer's is in carriers than in noncarriers.
It does not say whether one person will develop it. Lifetime chance gives the share expected to develop Alzheimer's by about age 85. That number is easier to picture.
- No APOE4 copy: about 9 in 100 develop Alzheimer's
- One copy: about 20–30 in 100 develop Alzheimer's
- Two copies: about 55–60 in 100 develop Alzheimer's
Does APOE4 change when symptoms appear?
APOE4, especially two copies, is linked to earlier symptom onset and earlier memory decline. It is also linked to more amyloid plaques in the brain. The 2024 Fortea study followed over 13,000 people across cohorts. Nearly all people with two APOE4 copies had abnormal amyloid in spinal fluid by age 65.
Mean symptom onset was 65.1 years. That pattern led researchers to describe two APOE4 copies as a distinct genetic form of Alzheimer's biology. It still does not fix an exact age for any person. Some carriers stay sharp much longer.
What can a carrier practically do next?
APOE4 is a risk gene, not a deterministic cause. Researchers estimate 40–65% of diagnosed Alzheimer's patients carry APOE-e4, according to the Alzheimer's Association in the Alzheimer's Association genetics page.
Many carriers never develop dementia, and many patients lack APOE4. Use the result as planning information, not a verdict. Bring the exact test wording, family history, and current memory concerns to a clinician or genetic counselor.
- Write down which test was done and the copy number
- List parents or siblings with dementia and ages at onset
- Note current memory, thinking, sleep, mood, and medicines
- Ask what follow-up, if any, fits age and health history
